FTC’s Low Blow On FOBs
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC concludes that extended brand exclusivity – or any generic exclusivity – is unnecessary for a robust follow-on biologics market.
You may also be interested in...
FDA And FTC Join Forces On Biosimilars
Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.
FDA, FTC Join Forces To Eliminate Barriers To Biosimilar Competition
Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.
Follow-On Biologics Theatre: Next Act Is FDA
A House subcommittee hearing on FTC’s report on FOB competition includes yelling, a “challenge” to take an FOB product – and a promise from Chairman Pallone for more of the same.